Literature DB >> 24084229

A systematic review of endoprosthetic replacement for non-tumour indications around the knee joint.

Muhammad T Korim1, Colin N A Esler, Venuthurla R M Reddy, Robert U Ashford.   

Abstract

BACKGROUND: Endoprosthetic replacement (EPR) for limb salvage is an established treatment modality for orthopaedic malignancies around the knee. Increasingly, they are being used for non-tumour indications such as fractures, bone loss associated with aseptic loosening, septic loosening and ligament insufficiencies.
METHODS: We reviewed the evolution and biomechanics of knee EPRs. MEDLINE was searched using the PubMed interface to identify relevant studies pertaining to the use of knee EPRs in non-tumour conditions. Failures, mortality and knee scores were the main outcome measures. Subgroup analysis in the non-tumour conditions was also performed.
RESULTS: There were nine studies with an average follow-up of 3.3years (Range 1-5years) describing 241 EPRs used in non-tumour conditions. Re-operation for any reason occurred in 17% (41/241) of cases. The most common complication was infection (15%) followed by aseptic loosening (5%) and periprosthetic fractures (5%). The mortality rate averaged 22%. Infected knee arthroplasties were less likely to have a successful outcome when salvaged with an EPR with failure rates up to 33%.
CONCLUSIONS: Endoprosthetic replacement is a limb salvage option when other surgical options are unfeasible, especially in low demand elderly patients with limited life expectancy. They have low rates of failure in the medium term. LEVEL OF EVIDENCE: Level 1.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Endoprosthetic replacement; Fractures; Knee; Massive bone loss; Survivorship; Tumour

Mesh:

Year:  2013        PMID: 24084229     DOI: 10.1016/j.knee.2013.09.001

Source DB:  PubMed          Journal:  Knee        ISSN: 0968-0160            Impact factor:   2.199


  7 in total

Review 1.  Megaprostheses in the treatment of periprosthetic fractures of the knee joint: indication, technique, results and review of literature.

Authors:  Reinhard Windhager; Markus Schreiner; Kevin Staats; Sebastian Apprich
Journal:  Int Orthop       Date:  2015-09-25       Impact factor: 3.075

2.  Megaprosthesis in distal femur non-unions in elderly patients-experience from twenty-four cases: a letter to editor.

Authors:  Raju Vaishya; Abhishek Vaish
Journal:  Int Orthop       Date:  2019-08-30       Impact factor: 3.075

3.  High reoperation and mortality rate after distal femoral replacement for periprosthetic knee fracture in the elderly.

Authors:  Oriol Pujol; Nayana Joshi-Jubert; Jorge H Nuñez; Joan Pijoan; Enric Castellet; Joan Minguell
Journal:  Eur J Orthop Surg Traumatol       Date:  2022-02-19

4.  The Performances of Conventional Titanium and Silver-Coated Megaprostheses in Non-oncological and Post-oncological Patients: An Analysis of Infection Failures in 142 Patients.

Authors:  Federico Sacchetti; Raphael Kilian; Francesco Muratori; Stephane Cherix; Lorenzo Foschi; Riccardo Morganti; Domenico Andrea Campanacci; Rodolfo Capanna
Journal:  Arch Bone Jt Surg       Date:  2022-05

5.  Distal Femoral Replacement and Extensor Mechanism Repair Reinforced With Synthetic Mesh for Distal Femur Fracture With Patellar Ligament Avulsion.

Authors:  Charles Powell; Kristopher Sanders; Neal Huang; Luis Felipe Colón; Colton Norton
Journal:  Arthroplast Today       Date:  2022-05-23

6.  Length of Endoprosthetic Reconstruction in Revision Knee Arthroplasty Is Associated With Complications and Reoperations.

Authors:  Jeffrey J Barry; Zachary Thielen; David C Sing; Paul H Yi; Erik N Hansen; Michael Ries
Journal:  Clin Orthop Relat Res       Date:  2017-01       Impact factor: 4.176

7.  Modular Endoprostheses for Nonneoplastic Conditions: Midterm Complications and Survival.

Authors:  Marco De Gori; Guido Scoccianti; Filippo Frenos; Leonardo Bettini; Filippo Familiari; Giorgio Gasparini; Giovanni Beltrami; Pierluigi Cuomo; Pietro De Biase; Rodolfo Capanna
Journal:  Biomed Res Int       Date:  2016-12-05       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.